Therapeutic Management of Patients with Metastatic BRAF-Mutated Melanoma: A Case Series Encompassing Different Clinical Scenarios

In the context of advanced BRAF-mutant melanoma, the treatment landscape has undergone a paradigm shift due to the impact of immune checkpoint inhibitors and BRAF/MEK inhibitors. This article presents three clinically illustrative melanoma cases that served as focal points for in-depth discussions during 12 expert meetings held across Spain. These include a treatment-naïve metastatic melanoma patient, a patient experiencing a recurrence while on anti-PD-1 adjuvant therapy, and a third patient whose melanoma relapsed ≥6 months after the end of adjuvant therapy. The discussions revolved around optimal treatment sequencing, emphasizing the challenges and alternatives discussed in each scenario. The common view aligned towards a nuanced approach that involves navigating the complexities of treatment choices. The conclusions underscore the need for personalized therapeutic strategies and highlight the ongoing challenge of refining real-life evidence-based algorithms for the management of metastatic BRAF-mutant melanoma.

Authors

Institutions

Publication Details

Journal
Onco
Published
2026-01-15
DOI
https://doi.org/10.3390/onco6010006
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Therapeutic Management of Patients with Metastatic BRAF-Mutated Melanoma: A Case Series Encompassing Different Clinical Scenarios

Roberto Efraín Díaz, María Quindós, Enrique Romerales Espinosa, Teresa Ubieto Puértolas et al.
Onco
Melanoma and MAPK Pathways
article

Therapeutic Management of Patients with Metastatic BRAF-Mutated Melanoma: A Case Series Encompassing Different Clinical Scenarios

Roberto Efraín Díaz, María Quindós, Enrique Romerales Espinosa, Teresa Ubieto Puértolas, E. Muñoz-Couselo, Margarita Majem, P. Ayala de Miguel, Almudena García Castaño, Gretel Benítez López, Ana Arance, Rafael López Castro, Rubén de Toro
article en

Abstract

In the context of advanced BRAF-mutant melanoma, the treatment landscape has undergone a paradigm shift due to the impact of immune checkpoint inhibitors and BRAF/MEK inhibitors. This article presents three clinically illustrative melanoma cases that served as focal points for in-depth discussions during 12 expert meetings held across Spain. These include a treatment-naïve metastatic melanoma patient, a patient experiencing a recurrence while on anti-PD-1 adjuvant therapy, and a third patient whose melanoma relapsed ≥6 months after the end of adjuvant therapy. The discussions revolved around optimal treatment sequencing, emphasizing the challenges and alternatives discussed in each scenario. The common view aligned towards a nuanced approach that involves navigating the complexities of treatment choices. The conclusions underscore the need for personalized therapeutic strategies and highlight the ongoing challenge of refining real-life evidence-based algorithms for the management of metastatic BRAF-mutant melanoma.

OncoVol. 6(1)
Hospital Universitario Insular de Gran Canaria (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital Universitario Virgen Macarena (ES), Marqués de Valdecilla University Hospital (ES), Hospital San Pedro de Alcántara (ES), Hospital Universitario Miguel Servet (ES), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Clínico Universitario de Valladolid (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Universidad Autónoma de Madrid (ES)
Pfizer, AstraZeneca, Sanofi, Helsinn, Les Laboratories Pierre Fabre, BeiGene, Moderna, Seagen, Sun Pharma, Helsinn Therapeutics
Openalex Percentile: Top 88%
Melanoma and MAPK Pathways
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.